ES2646320T3 - Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo - Google Patents

Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo Download PDF

Info

Publication number
ES2646320T3
ES2646320T3 ES10715098.9T ES10715098T ES2646320T3 ES 2646320 T3 ES2646320 T3 ES 2646320T3 ES 10715098 T ES10715098 T ES 10715098T ES 2646320 T3 ES2646320 T3 ES 2646320T3
Authority
ES
Spain
Prior art keywords
glycan
jejuni
wbap
salmonella enterica
presents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10715098.9T
Other languages
English (en)
Inventor
Karin Ilg
Markus Aebi
Umesh Ahuja
Saba Amber
Flavio Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eidgenoessische Technische Hochschule Zurich ETHZ
Original Assignee
Eidgenoessische Technische Hochschule Zurich ETHZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidgenoessische Technische Hochschule Zurich ETHZ filed Critical Eidgenoessische Technische Hochschule Zurich ETHZ
Application granted granted Critical
Publication of ES2646320T3 publication Critical patent/ES2646320T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Salmonella enterica, caracterizada por que comprende al menos un operón pgl (para la glicosilación de proteínas) de Campylobacter jejuni o un derivado funcional del mismo y presenta sobre su superficie celular al menos un N-glicano de Campylobacter jejuni o un derivado de N-glicano del mismo, en donde están inactivados uno más genes de la biosíntesis de bacilosamina por mutación y/o deleción parcial o completa, preferiblemente por deleción parcial y/o completa de los genes pgI, D, E, F.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
Capacidad de colonización de ∆wbaP en un experimento de co-infección
La capacidad de colonización de S. Typhimurium ∆wbaP se probó en un experimento de co-infección en el cual los ratones se infectaron intragástricamente con el mutante ∆wbaP, así como con la cepa tipo silvestre. Los ratones 5 C57BL/6 (SPF, colonia del RCHCl, Zurich) se pre-trataron mediante sonda gástrica con 20 mg de estreptomicina. Veinticuatro horas después los ratones se inocularon con 5 x 107 UFC de la cepa serovar Typhimurium o las mezclas de las cepas como se indica. Las cargas bacterianas (UFC) en sedimentos fecales frescos, nodos linfoides mesentéricos (mLN), bazo, y contenido cecal se determinaron mediante la siembra en placas sobre placas de agar MacConkey (50 µg/ml de estreptomicina) como se ha descrito anteriormente (Barthel, Hapfelmeier et al. 2003). Los 10 índices competitivos (CI) se determinaron de acuerdo con la fórmula CI= (mutante/tipo silvestre) salida/(mutante/tipo silvestre) entrada después de la siembra en placa. Se realizó un experimento de co-infección de serovar Typhimurium tipo silvestre (M939) y la cepa ∆wbaP (SKI11). Cinco ratones tratados con estreptomicina se infectaron con una mezcla 1:2 (total 5 X 107 UFC) intragástricamente de la cepa ∆wbaP (SKI11) y la cepa tipo silvestre. La proporción de las 2 cepas (CI; índice competitivo, véase Materiales y Métodos) se determinó en las heces en el día 15 1, 2 y 3 p.i. Se detectó una disminución de los recuentos de ∆wbaP (SKI11) en comparación con el tipo silvestre (una escala logarítmica por día) y se probó que la cepa ∆wbaP (SKI11) de hecho tuvo un defecto competitivo importante en comparación con la cepa serovar Typhimurium tipo silvestre en el tracto intestinal (p>0,05; figura 4A). Además, el CI de las dos cepas en los sitios sistémicos (mLN, hígado, bazo) en el día 4 p.i. también demostró un defecto competitivo significativo de serovar Typhimurium ∆wbaP (SKI12). Sin embargo, el defecto era menos
20 pronunciado que en el intestino (Figura 4B).
Tabla 1: Cepas, plásmidos y cebadores para la deleción de wbaP utilizados en este trabajo
Cepas de Salmonella enterica sv Typhimurium
Cepa
Genotipo y fenotipo Fuente de la referencia
SL1344
tipo silvestre; strepR Hoiseth, S. K. and B. A. Stocker, Nature 291:238-239, 1981
SKI11
SL1344∆wbaP::cat; strepR , cam R este estudio
SKI12
SL1344∆wbaP; strepR este estudio
SKI34
SKI12::pKI14; strepR, tetR este estudio
SKI35
SKI12::pKI15; strepR, tetR este estudio
Cepas de Escherichia coli
DH5a
SupE44 ∆lacU169 (Φ80lacZ∆M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Hanahan, D., J. Mol. Biol., 5,166(4):557-80, 1983
CC118 λpir
∆(ara-leu), araD, ∆lacX74, galE, galK, phoA20, thi-1, rpsE, rpoB, argE(Am), recA, λpir Herrero, M., V. de Lorenzo, and K. N. Timmis. J Bacteriol 172:6557-6567.
Sm10λpir
thi thr leu tonA lacY supE recA::RP4 2-Tc::Mu λpir, kanR Miller, V. L. and J. J. Mekalanos. J. Bacteriol. 170:2575-2583, 1988.
Plásmidos
Plásmido
Genotipo Fuente de referencia
pSB377
tetR oriR6K Mirold et al., Proc. Natl. Acad. Sci. USA, 96:9845-9850, 1999.
pKD3
bla FRT cat FRT PS1 Datsenko, K. A. and B. L.
PS2 oriR6K
Wanner, Proc. Natl. Acad. Sci. USA, 97:6640-6645, 2000.
pKD46
bla PBAD gam bet exo pSC101 oriTS Datsenko, K. A., and B. L. Wanner, Proc. Natl. Acad. Sci. USA, 97:66406645, 2000.
pCP20
bla cat cl857 λPR flp pSC101 oriTS Datsenko, K. A., and B. L. Wanner,Proc. Natl. Acad. Sci. USA, 97:6640-6645, 2000
pACYC184
CmR, TcR, ori p15A New England Biolabs
pACYCpglmut
CmR, ori p15A; grupo C. jejuni pgl con pglBW458A,D459A clonado en pACYC184 Science, 298(5599):1790-3, 29. Nov. 2002
pACYCpgl3mut
CmR, ori p15A; grupo C. jejuni pgl con pglBW458A,D459A clonado en pACYC184, deleción en pglE, F, G y 3'-mitad de pglD Este estudio
pKI14
TetR, oriR6K, región de 500 pb 3' de PagC clonado en pSB377 Este estudio
pKI15
TetR, oriR6K, grupo C. jejuni pgl3mut con pglBW458A,D459A clonado en pKI15 Este estudio
Cebadores para la delación de wbaP
RfbP H1P1
12

Claims (1)

  1. imagen1
    imagen2
ES10715098.9T 2009-03-27 2010-03-25 Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo Active ES2646320T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09004445 2009-03-27
EP09004445 2009-03-27
PCT/EP2010/001884 WO2010108682A1 (en) 2009-03-27 2010-03-25 Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof

Publications (1)

Publication Number Publication Date
ES2646320T3 true ES2646320T3 (es) 2017-12-13

Family

ID=42199060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10715098.9T Active ES2646320T3 (es) 2009-03-27 2010-03-25 Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo

Country Status (14)

Country Link
US (2) US9309493B2 (es)
EP (1) EP2411503B1 (es)
JP (1) JP5568626B2 (es)
KR (1) KR101395431B1 (es)
CN (1) CN102365359B (es)
BR (1) BRPI1010283B8 (es)
CA (1) CA2757224C (es)
ES (1) ES2646320T3 (es)
IL (1) IL215239A (es)
MX (1) MX2011009791A (es)
PL (1) PL2411503T3 (es)
PT (1) PT2411503T (es)
RU (1) RU2507253C2 (es)
WO (1) WO2010108682A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2501406T3 (es) 2009-11-19 2018-05-19
US20140336366A1 (en) * 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
WO2013159234A1 (en) 2012-04-27 2013-10-31 The Governors Of The University Of Alberta Glycoengineered outer membrane vesicles and use thereof as vaccines
RU2671473C2 (ru) * 2013-04-05 2018-10-31 Де Гавенерс Оф Де Юниверсити Оф Альберта Вакцина против кампилобактериоза
CN103740632B (zh) * 2014-01-22 2016-02-10 山东大学 一株重组大肠杆菌及其在制备抗o157:h7的n-糖蛋白疫苗中的应用
BR112019015425A2 (pt) 2017-01-27 2020-05-26 University Of Florida Research Foundation, Incorporated Uma vacina de segurança alimentar para controlar salmonella enterica e reduzir campylobacter em aves domésticas
WO2018167485A1 (en) 2017-03-15 2018-09-20 London School Of Hygiene And Tropical Medicine Whole cell vaccines
PE20171768A1 (es) * 2017-06-12 2017-12-21 Farm Veterinarios S A C Obtencion de una salmonela enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar
EP3727437A4 (en) * 2017-12-19 2021-09-08 The Governors of the University of Alberta SURFACE GLYCANES OF CLOSTRIDIUM PERFRINGENS AND ASSOCIATED USES
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN116286580A (zh) * 2023-03-24 2023-06-23 山东大学 一种工程微生物及趋化受体的配体筛选方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399074B1 (en) * 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
ATE426035T1 (de) * 2001-05-03 2009-04-15 Fit Biotech Oy Neue expressionsvektoren und deren verwendungen
WO2004013151A2 (en) * 2002-08-01 2004-02-12 National Research Council Of Canada Campylobacter glycans and glycopeptides
RU2237089C2 (ru) * 2002-10-31 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Рекомбинантный аттенуированный штамм бактерий salmonella enteriditis е-23/pgex-2t-tbi как кандидат для конструирования живой вакцины против вируса иммунодефицита человека
ES2345200T3 (es) * 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
RU2248396C2 (ru) * 2003-04-17 2005-03-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Рекомбинантная плазмидная днк pcdna-tci, обеспечивающая экспрессию искусственного гена tci в клетках эукариот, и рекомбинантный аттенуированный штамм бактерий salmonella enteritidis e-23/pcdna-tci как кандидат для конструирования живой днк-вакцины против вируса иммунодефицита человека
EP1655370A1 (en) * 2004-11-05 2006-05-10 Gesellschaft für Biotechnologische Forschung Bacterial vector
ES2353814T3 (es) * 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
AU2006295017B2 (en) 2005-09-21 2010-06-17 The United States Of America As Represented By The Secretary Of The Navy Immunogenic capsule composition for use as a vaccine component against Campylobacter jejuni

Also Published As

Publication number Publication date
KR20110127714A (ko) 2011-11-25
US20120100177A1 (en) 2012-04-26
RU2507253C2 (ru) 2014-02-20
EP2411503B1 (en) 2017-09-13
CN102365359B (zh) 2014-10-29
BRPI1010283A2 (pt) 2016-10-11
CA2757224C (en) 2016-12-06
PL2411503T3 (pl) 2018-01-31
EP2411503A1 (en) 2012-02-01
WO2010108682A1 (en) 2010-09-30
JP2012521747A (ja) 2012-09-20
BRPI1010283B8 (pt) 2021-05-25
JP5568626B2 (ja) 2014-08-06
US20160213770A1 (en) 2016-07-28
CN102365359A (zh) 2012-02-29
BRPI1010283B1 (pt) 2021-04-06
US9309493B2 (en) 2016-04-12
MX2011009791A (es) 2011-10-17
CA2757224A1 (en) 2010-09-30
RU2011143381A (ru) 2013-05-10
KR101395431B1 (ko) 2014-05-14
PT2411503T (pt) 2017-11-15
US9764021B2 (en) 2017-09-19
IL215239A (en) 2016-02-29
IL215239A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
ES2646320T3 (es) Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo
Okoro et al. Signatures of adaptation in human invasive Salmonella Typhimurium ST313 populations from sub-Saharan Africa
Wiles et al. Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium
US20230250138A1 (en) Virulence Attenuated Bacteria Based Protein Delivery
Kingsley et al. Genome and transcriptome adaptation accompanying emergence of the definitive type 2 host-restricted Salmonella enterica serovar Typhimurium pathovar
Que et al. Salmonella pathogenicity island 1 (SPI-1) at work
Cohen et al. Pathoadaptation of the passerine-associated Salmonella enterica serovar Typhimurium lineage to the avian host
Ilg et al. O-antigen-negative Salmonella enterica serovar Typhimurium is attenuated in intestinal colonization but elicits colitis in streptomycin-treated mice
Yang et al. Characterization of the invasive, multidrug resistant non-typhoidal Salmonella strain D23580 in a murine model of infection
Pati et al. Deletion of invH gene in Salmonella enterica serovar Typhimurium limits the secretion of Sip effector proteins
Mudrak et al. The Vibrio cholerae Pst2 phosphate transport system is upregulated in biofilms and contributes to biofilm-induced hyperinfectivity
Rodríguez-Morales et al. Salmonella enterica serovar Typhimurium ompS1 and ompS2 mutants are attenuated for virulence in mice
Tsolis et al. SspA is required for lethal Salmonella enterica serovar Typhimurium infections in calves but is not essential for diarrhea
Fu et al. The response regulator OmpR contributes to the pathogenicity of avian pathogenic Escherichia coli
Elder et al. Genomic organization and role of SPI-13 in nutritional fitness of Salmonella
Tatsuno et al. The lpf gene cluster for long polar fimbriae is not involved in adherence of enteropathogenic Escherichia coli or virulence of Citrobacter rodentium
Cherayil et al. Salmonella enterica serovar typhimurium-dependent regulation of inducible nitric oxide synthase expression in macrophages by invasins SipB, SipC, and SipD and effector SopE2
Winter et al. Formate oxidation in the intestinal mucus layer enhances fitness of Salmonella enterica serovar Typhimurium
Yu et al. Dietary L-arabinose-induced gut dysbiosis exacerbates Salmonella infection outcome
Holden et al. Avian pathogenic Escherichia coli ΔtonB mutants are safe and protective live-attenuated vaccine candidates
Altinok et al. Succinate dehydrogenase mutant of Listonella anguillarum protects rainbow trout against vibriosis
Zhu et al. The possible influence of LuxS in the in vivo virulence of rabbit enteropathogenic Escherichia coli
Mo et al. Phenotypic characterization, virulence, and immunogenicity of Edwardsiella tarda LSE40 aroA mutant
Wellawa et al. Characterization of colonization kinetics and virulence potential of Salmonella Enteritidis in chickens by photonic detection
Frana et al. Effects of microcin 24-producing Escherichia coli on shedding and multiple-antimicrobial resistance of Salmonella enterica serotype Typhimurium in pigs